Mermisi Llc

Mermisi LLC, established in 1993, is a privately held pharmaceutical company headquartered in Tbilisi, Georgia. Specializing in the registration, import, and distribution of pharmaceutical products, Mermisi has been a leader in the Georgian pharmaceutical sector for over three decades. The company focuses on introducing innovative medical products, including targeted anticancer medicines, biosimilars, and advanced biologic and nanotechnologically advanced drugs, thereby contributing significantly to public health and welfare in Georgia. (mermisi.ge)

With a team of 11-50 employees, Mermisi LLC has developed strong partnerships with global pharmaceutical manufacturers, facilitating the launch and scaling of oncology products in Georgia. Their comprehensive services encompass regulatory approval, reimbursement, distribution, promotion, and long-term market growth, positioning them as a preferred partner for market entry and commercial success in Georgia's specialty pharmaceutical sector. (mermisi.ge)

Mermisi LLC operates a centralized distribution network from its headquarters in Tbilisi, Georgia. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's extensive experience and partnerships suggest a well-established infrastructure capable of efficiently managing the import and distribution of pharmaceutical products across Georgia. Their focus on oncology and specialty pharmaceuticals indicates a strategic approach to logistics, ensuring timely and reliable delivery to healthcare providers nationwide.

In Georgia's pharmaceutical supply chain, Mermisi LLC functions primarily as a pharmaceutical importer and distributor. The company plays a pivotal role in introducing and supplying innovative medical products, particularly in the oncology and specialty sectors, to the Georgian market. By partnering with global manufacturers, Mermisi ensures the availability of advanced therapies, thereby enhancing the quality of healthcare services in the country. (mermisi.ge)

Mermisi LLC's sourcing strategy reveals a significant concentration on a select group of suppliers. The company's total import value from India amounts to $2.3 million USD, with 63 shipments covering five products across three therapeutic categories. The top five products imported include Paclitaxel and Protein, each valued at $1.1 million USD, accounting for 1.4% and 7.1% of the total share, respectively. This concentration indicates a strategic choice to focus on high-value, specialized products, potentially leveraging supplier expertise and favorable pricing.

The shipment data, with 55 shipments from GETWELL PHARMA INDIA PRIVATE LIMITED and 20 from GETWELL PHARMACEUTICALS, suggests a stable and ongoing relationship with these suppliers. However, the reliance on a limited number of suppliers may pose risks related to supply chain disruptions or changes in supplier dynamics. Diversifying the supplier base could mitigate such risks and enhance supply chain resilience.

Mermisi LLC's supply chain resilience appears robust, given the company's longstanding partnerships with key Indian suppliers. The diversity in imported formulations, with 88 unique products, indicates a broad sourcing strategy within the oncology and specialty pharmaceutical sectors. While the primary suppliers are GETWELL PHARMA INDIA PRIVATE LIMITED and GETWELL PHARMACEUTICALS, the presence of additional suppliers like G P INTERGLOBE and THERDOSE PHARMA PRIVATE LIMITED suggests a level of diversification.

However, the concentration on a few suppliers may expose Mermisi LLC to risks such as supply chain disruptions or changes in supplier dynamics. To enhance resilience, the company could consider expanding its supplier base and exploring alternative sourcing options. Ensuring that all suppliers comply with Good Manufacturing Practice (GMP) standards is crucial for maintaining product quality and regulatory compliance.

Mermisi LLC's focused sourcing strategy positions the company as a key player in the oncology and specialty pharmaceutical markets in Georgia. By importing high-value products like Paclitaxel and Protein, Mermisi demonstrates a commitment to providing advanced therapies to the Georgian healthcare system. This strategic focus allows the company to build strong relationships with suppliers and establish a reputation for quality and reliability.

For Indian exporters, Mermisi LLC represents a valuable partner for distributing specialized pharmaceutical products in Georgia. Understanding Mermisi's product preferences and regulatory requirements can facilitate smoother market entry and collaboration. Expanding the supplier base and offering a diverse range of formulations could further strengthen Mermisi's market position and provide additional opportunities for Indian exporters.

In Georgia, the regulation of pharmaceutical products is overseen by the Agency of State Regulation of Medical Activities at the Ministry of Labor, Health and Social Protection. This agency is responsible for the registration, import, and distribution of pharmaceutical products, ensuring compliance with national and international standards. The legal framework governing pharmaceutical activities includes the Law of Georgia on Medicines and Pharmaceutical Activities, which outlines the procedures for drug registration, importation, and distribution. (matsne.gov.ge)

The registration process for pharmaceutical products in Georgia can be conducted through two regimes: national and recognition. The recognition regime allows for the simplified registration of drugs already approved by stringent regulatory authorities, such as the European Medicines Agency (EMA) or the U.S. Food and Drug Administration (FDA), without the need for re-testing. This facilitates faster market entry for products that have already undergone rigorous evaluation. (mkdlaw.ge)

Importing pharmaceutical products into Georgia requires obtaining a specific permit from the Regulation Agency. Additionally, warehouses must meet Good Distribution Practice (GDP) standards to ensure the quality and integrity of the products during storage and transportation. Compliance with GDP is mandatory for pharmaceutical distributors in Georgia, as it ensures that medicines are consistently stored, transported, and handled under suitable conditions. (legal.ge)

Good Manufacturing Practice (GMP) certification is also mandatory for pharmaceutical manufacturers in Georgia. This certification ensures that products are consistently produced and controlled according to quality standards, thereby safeguarding public health. For importers and distributors, recognizing GMP certificates from reputable authorities, such as the European Union (EU) GMP, World Health Organization (WHO) GMP, or Pharmaceutical Inspection Co-operation Scheme (PIC/S), is essential for maintaining product quality and regulatory compliance. (legal.ge)

Pharmaceutical products imported into Georgia must undergo batch testing to ensure they meet the required quality standards. Stability studies are also conducted to determine the shelf life and storage conditions of the products. Labeling requirements stipulate that all information, including the Patient Information Leaflet (PIL), must be provided in the Georgian language. This ensures that patients and healthcare providers can accurately understand the product's usage, dosage, and potential side effects. (legal.ge)

Serialization mandates are in place to enhance traceability and prevent counterfeit products from entering the market. These requirements involve assigning a unique serial number to each saleable unit of a pharmaceutical product, facilitating tracking throughout the supply chain. Compliance with these standards is crucial for maintaining the integrity of the pharmaceutical supply chain and ensuring patient safety.

Between 2024 and 2026, Georgia has implemented several policy changes affecting pharmaceutical imports. Notably, the country has introduced a reference pricing system for a specific list of essential medicines, setting price caps to make medications more affordable. Selling above the reference price is illegal and results in fines. Additionally, compliance with Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) standards has been made mandatory for manufacturers, importers, and distributors since 2022, ensuring consistent product quality and safety. (legal.ge)

Mermisi LLC's product strategy focuses on high-value, specialized pharmaceutical products, particularly in the oncology and specialty sectors. The company's top five imported products—Paclitaxel, Protein, Pembrolizumab, Daratumumab, and Pazopanib—align with this focus, addressing critical therapeutic areas with significant market demand. This strategic emphasis allows Mermisi to meet the needs of patients requiring advanced therapies and positions the company as a leader in providing innovative treatments in Georgia. (mermisi.ge)

The market demand for these products is driven by the increasing prevalence of cancer and other complex diseases in Georgia, necessitating access to cutting-edge treatments. By importing these specialized products, Mermisi LLC contributes to improving patient outcomes and advancing the standard of care in the country.

Mermisi LLC's sourcing strategy is centered on importing finished pharmaceutical formulations from India, focusing on generic drugs and specialized formulations. The company's preference for finished products allows for quicker market entry and ensures that the imported medicines are ready for distribution without the need for additional processing. India's robust pharmaceutical manufacturing sector, known for its compliance with international quality standards, makes it a strategic sourcing partner for Mermisi.